<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="78926"><DrugName>interleukin-2 follow-on biologic, Beijing SL Pharmaceutical</DrugName><DrugNamesKey><Name id="42983539">Xin Ji Er</Name></DrugNamesKey><DrugSynonyms><Name><Value>interleukin-2</Value></Name><Name><Value>interleukin-2 follow-on biologic, Beijing SL Pharmaceutical</Value></Name><Name><Value>Xin Ji Er</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>IL-2</Value></Name><Name><Value>IL-2 follow-on biologic, Beijing SL Pharmaceutical</Value></Name></DrugSynonyms><CompanyOriginator id="1047948">Beijing SL Pharmaceutical Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1047948" type="Company"><TargetEntity id="4295865485" type="organizationId">Beijing SL Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="203" type="ciIndication"><TargetEntity id="10025310" type="MEDDRA"></TargetEntity><TargetEntity id="D008223" type="MeSH"></TargetEntity><TargetEntity id="-386134440" type="omicsDisease"></TargetEntity><TargetEntity id="698" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="205" type="ciIndication"><TargetEntity id="C43" type="ICD10"></TargetEntity><TargetEntity id="10025650" type="MEDDRA"></TargetEntity><TargetEntity id="D008545" type="MeSH"></TargetEntity><TargetEntity id="-361092282" type="omicsDisease"></TargetEntity><TargetEntity id="705" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2204" type="ciIndication"><TargetEntity id="R18" type="ICD10"></TargetEntity><TargetEntity id="789.5" type="ICD9"></TargetEntity><TargetEntity id="10003445" type="MEDDRA"></TargetEntity><TargetEntity id="D001201" type="MeSH"></TargetEntity><TargetEntity id="-1050760240" type="omicsDisease"></TargetEntity><TargetEntity id="417" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="746" type="ciIndication"><TargetEntity id="10021789" type="MEDDRA"></TargetEntity><TargetEntity id="D007239" type="MeSH"></TargetEntity><TargetEntity id="-367065996" type="omicsDisease"></TargetEntity><TargetEntity id="799" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="755" type="ciIndication"><TargetEntity id="C34" type="ICD10"></TargetEntity><TargetEntity id="10062042" type="MEDDRA"></TargetEntity><TargetEntity id="D008175" type="MeSH"></TargetEntity><TargetEntity id="-243902424" type="omicsDisease"></TargetEntity><TargetEntity id="611" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="999" type="ciIndication"><TargetEntity id="C64" type="ICD10"></TargetEntity><TargetEntity id="10038389" type="MEDDRA"></TargetEntity><TargetEntity id="D007680" type="MeSH"></TargetEntity><TargetEntity id="-1866040075" type="omicsDisease"></TargetEntity><TargetEntity id="607" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="PTGT-03144" type="ciTarget"><TargetEntity id="10103482135583" type="siTarget">Interleukin-2</TargetEntity><TargetEntity id="398" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Ascites - China - Dec-1999</FirstLaunched><FirstLaunched>Infectious disease - China - Dec-1999</FirstLaunched><FirstLaunched>Lung tumor - China - Dec-1999</FirstLaunched><FirstLaunched>Lymphoma - China - Dec-1999</FirstLaunched><FirstLaunched>Melanoma - China - Dec-1999</FirstLaunched><FirstLaunched>Renal tumor - China - Dec-1999</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="203">Lymphoma</Indication><Indication id="205">Melanoma</Indication><Indication id="2204">Ascites</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="746">Infectious disease</Indication><Indication id="755">Lung tumor</Indication><Indication id="999">Renal tumor</Indication></IndicationsPrimary><ActionsPrimary><Action id="12481">Interleukin-2 ligand</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="647">Subcutaneous formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="961">Follow on biological product</Technology><Technology id="85">Protein recombinant</Technology></Technologies><LastModificationDate>2017-08-03T14:06:51.000Z</LastModificationDate><ChangeDateLast>2015-11-23T00:00:00.000Z</ChangeDateLast><AddedDate>2012-06-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1047948" linkType="Company"&gt;Beijing SL Pharmaceutical&lt;/ulink&gt; has developed and launched  an  injectable formulation of  recombinant human interleukin-2 (IL-2,  Xin Ji Er ), a follow-on biologic of  interleukin-2, for the treatment of  renal cancer and malignant melanoma, malignant lymphoma, lung cancer, ascites and infection disease [&lt;ulink linkID="1304015" linkType="Reference"&gt;1304015&lt;/ulink&gt;]. The company is also developing the program,  for the potential  sc treatment of  rheumatoid arthritis. In November 2015, a phase II trial was initiated. At that time, the trial was expected to complete in June 2017  [&lt;ulink linkID="1670839" linkType="Reference"&gt;1670839&lt;/ulink&gt;]. In March 1999, the drug was approved by the SFDA and the launch took place shortly after [&lt;ulink linkID="1304015" linkType="Reference"&gt;1304015&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In June 2015, a randomized, double blind, placebo-controlled, phase II pilot-study (&lt;ulink linkID="231708" linkType="Protocol"&gt;NCT02467504&lt;/ulink&gt;; hrIL-2 RA)  to evaluate efficacy and safety of low-dose recombinant human IL-2 in combination with methotrexate (MTX) and &lt;ulink linkID="44301" linkType="Drug"&gt;loxoprofen&lt;/ulink&gt; compared to placebo plus MTX and loxoprofen, in disease modifying antirheumatic drugs (DMARD)-naive patients (expected n =  60) with rheumatoid arthritis, was expected to begin in July 2015. The study was expected to complete in June 2017; in November 2015, the trial was initiated [&lt;ulink linkID="1670839" linkType="Reference"&gt;1670839&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 1997, the drug was approved for clinical trials in China [&lt;ulink linkID="1304015" linkType="Reference"&gt;1304015&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="999">Renal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-12-31T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-12-31T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="746">Infectious disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-12-31T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-12-31T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="755">Lung tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-12-31T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2204">Ascites</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-12-31T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-10T00:00:00.000Z</StatusDate><Source id="1670839" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-06-30T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="755">Lung tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-06-30T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="2204">Ascites</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-06-30T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="999">Renal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-06-30T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-06-30T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="746">Infectious disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-06-30T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-03-31T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="755">Lung tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-03-31T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2204">Ascites</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-03-31T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="999">Renal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-03-31T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-03-31T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="746">Infectious disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-03-31T00:00:00.000Z</StatusDate><Source id="1304015" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047948">Beijing SL Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-06-04T00:00:00.000Z</StatusDate><Source id="1670839" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-03144"><Name>Interleukin-2 ligand</Name><SwissprotNumbers><Swissprot>O62641</Swissprot><Swissprot>O77620</Swissprot><Swissprot>O97513</Swissprot><Swissprot>P04351</Swissprot><Swissprot>P05016</Swissprot><Swissprot>P17108</Swissprot><Swissprot>P19114</Swissprot><Swissprot>P26891</Swissprot><Swissprot>P36835</Swissprot><Swissprot>P37997</Swissprot><Swissprot>P46649</Swissprot><Swissprot>P51747</Swissprot><Swissprot>P60568</Swissprot><Swissprot>P60569</Swissprot><Swissprot>P68290</Swissprot><Swissprot>P68291</Swissprot><Swissprot>Q07885</Swissprot><Swissprot>Q08081</Swissprot><Swissprot>Q08867</Swissprot><Swissprot>Q29416</Swissprot><Swissprot>Q29615</Swissprot><Swissprot>Q5MBA8</Swissprot><Swissprot>Q7JFM3</Swissprot><Swissprot>Q7JFM4</Swissprot><Swissprot>Q7JFM5</Swissprot><Swissprot>Q865X2</Swissprot><Swissprot>Q865Y1</Swissprot><Swissprot>Q8MKH2</Swissprot><Swissprot>Q95KP3</Swissprot><Swissprot>Q9XS38</Swissprot><Swissprot>Q9XT83</Swissprot><Swissprot>Q9XT84</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="523025" number="WO-2011106991" title="One kind of complex molecules of protein polypeptide and application thereof"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing SL Pharmaceutical Co Ltd" id="1047948"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>